Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of JW0108 + C2407 in Dyslipidemia
NCT06955104Phase 3Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Apr 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia comparing JW0108 + C2407 with JW0108 + Placebo (2 arms). Primary endpoint: Percent change from baseline in LDL-C at Week 8. Started Apr 2025; status: completed.
02
Drugs
CST-2032
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT06955104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06955104.